A case for drug treatment of obesity.
Several brain receptor systems can modulate food intake. Thus, in a new strategy against obesity, the patient takes submaximal doses of two drugs that act by differing mechanisms.
Bray
G A
GA
Pennington Biomedical Research Center, Louisiana State University, Baton Rouge.
D000318:Adrenergic beta-Agonists / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D001067:Appetite Depressants / Q000145:classification / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use; D001294:Attitude to Health; D004983:Ethanolamines / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D013006:Growth Hormone / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D008049:Lipase / Q000037:antagonists & inhibitors; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D012008:Recurrence; D013739:Testosterone / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D017211:Treatment Failure
D000318:Adrenergic beta-Agonists; D001067:Appetite Depressants; D004983:Ethanolamines; D007783:Lactones; D013739:Testosterone; C039248:BRL 26830A; D013006:Growth Hormone; D000077403:Orlistat; D008049:Lipase